Request RejectedThe requested URL was rejected. If you think this is an error, please contact the webmaster.

Your support ID is: 10880050419939738643

Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Recent Press Releases

Dec 9, 2014
Dynavax Announces Webcast of R&D Day

Dec 8, 2014
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Corporate Presentation

Annual Report and Proxy
2014 Proxy Statement
2013 Form 10-K